These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1058 related articles for article (PubMed ID: 32754159)

  • 1. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.
    Bhaskar S; Sinha A; Banach M; Mittoo S; Weissert R; Kass JS; Rajagopal S; Pai AR; Kutty S
    Front Immunol; 2020; 11():1648. PubMed ID: 32754159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19.
    Wu Y; Huang X; Sun J; Xie T; Lei Y; Muhammad J; Li X; Zeng X; Zhou F; Qin H; Shao L; Zhang Q
    mSphere; 2020 Jul; 5(4):. PubMed ID: 32669467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Science Underlying COVID-19: Implications for the Cardiovascular System.
    Liu PP; Blet A; Smyth D; Li H
    Circulation; 2020 Jul; 142(1):68-78. PubMed ID: 32293910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
    Tang Y; Liu J; Zhang D; Xu Z; Ji J; Wen C
    Front Immunol; 2020; 11():1708. PubMed ID: 32754163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine storm intervention in the early stages of COVID-19 pneumonia.
    Sun X; Wang T; Cai D; Hu Z; Chen J; Liao H; Zhi L; Wei H; Zhang Z; Qiu Y; Wang J; Wang A
    Cytokine Growth Factor Rev; 2020 Jun; 53():38-42. PubMed ID: 32360420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe COVID-19: what have we learned with the immunopathogenesis?
    Bordallo B; Bellas M; Cortez AF; Vieira M; Pinheiro M
    Adv Rheumatol; 2020 Sep; 60(1):50. PubMed ID: 32962761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
    Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
    Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
    Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
    Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
    Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
    Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
    Quirch M; Lee J; Rehman S
    J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine storm induced by SARS-CoV-2.
    Song P; Li W; Xie J; Hou Y; You C
    Clin Chim Acta; 2020 Oct; 509():280-287. PubMed ID: 32531256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.
    Weiskopf D; Schmitz KS; Raadsen MP; Grifoni A; Okba NMA; Endeman H; van den Akker JPC; Molenkamp R; Koopmans MPG; van Gorp ECM; Haagmans BL; de Swart RL; Sette A; de Vries RD
    Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32591408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular underpinning of COVID-19.
    Wazny V; Siau A; Wu KX; Cheung C
    Open Biol; 2020 Aug; 10(8):200208. PubMed ID: 32847471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
    Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
    Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
    Atluri S; Manchikanti L; Hirsch JA
    Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Immune Response and Immunopathology of COVID-19.
    Mortaz E; Tabarsi P; Varahram M; Folkerts G; Adcock IM
    Front Immunol; 2020; 11():2037. PubMed ID: 32983152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications.
    Pelaia C; Tinello C; Vatrella A; De Sarro G; Pelaia G
    Ther Adv Respir Dis; 2020; 14():1753466620933508. PubMed ID: 32539627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tackling the cytokine storm in COVID-19, challenges and hopes.
    Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA
    Life Sci; 2020 Sep; 257():118054. PubMed ID: 32663575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.